期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 10, 期 16, 页码 2745-2757出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560903302265
关键词
DPP-IV inhibitors; oral hypoglycaemic; type 2 diabetes; vildagliptin
Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据